VYNE Therapeutics (NASDAQ:VYNE – Get Free Report) and Vivani Medical (NASDAQ:VANI – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.
Volatility and Risk
VYNE Therapeutics has a beta of 2, meaning that its stock price is 100% more volatile than the S&P 500. Comparatively, Vivani Medical has a beta of 3.17, meaning that its stock price is 217% more volatile than the S&P 500.
Insider & Institutional Ownership
83.8% of VYNE Therapeutics shares are held by institutional investors. Comparatively, 6.8% of Vivani Medical shares are held by institutional investors. 3.0% of VYNE Therapeutics shares are held by insiders. Comparatively, 46.4% of Vivani Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| VYNE Therapeutics | -4,646.14% | -74.86% | -63.87% |
| Vivani Medical | N/A | -293.64% | -79.49% |
Analyst Ratings
This is a breakdown of current ratings for VYNE Therapeutics and Vivani Medical, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| VYNE Therapeutics | 1 | 3 | 0 | 0 | 1.75 |
| Vivani Medical | 1 | 1 | 1 | 0 | 2.00 |
VYNE Therapeutics currently has a consensus price target of $4.50, suggesting a potential upside of 661.04%. Vivani Medical has a consensus price target of $4.00, suggesting a potential upside of 263.64%. Given VYNE Therapeutics’ higher probable upside, equities research analysts clearly believe VYNE Therapeutics is more favorable than Vivani Medical.
Earnings and Valuation
This table compares VYNE Therapeutics and Vivani Medical”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| VYNE Therapeutics | $570,000.00 | 34.57 | -$26.48 million | ($0.78) | -0.76 |
| Vivani Medical | N/A | N/A | -$23.49 million | ($0.45) | -2.44 |
Vivani Medical has lower revenue, but higher earnings than VYNE Therapeutics. Vivani Medical is trading at a lower price-to-earnings ratio than VYNE Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Vivani Medical beats VYNE Therapeutics on 7 of the 13 factors compared between the two stocks.
About VYNE Therapeutics
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
About Vivani Medical
Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.
Receive News & Ratings for VYNE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VYNE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
